Company intelligence / Profile preview

Zionexa

Ownership: Private
Employees: ~24
Development stage: Commercial

Overview

Zionexa developed and commercialized molecular imaging solutions and companion diagnostics to guide targeted therapies in oncology. Its lead product, Cerianna ([18F]-fluoroestradiol), received FDA clearance in May 2020 as a PET imaging agent to detect estrogen receptor-positive lesions for treatment selection in recurrent or metastatic breast cancer. The company was acquired by GE Healthcare in May 2021. At acquisition, it had about two dozen employees and aimed to expand access to its diagnostic technology across the US.

Therapeutic areas: OncologyNeurology
Modalities: Molecular imaging agentsin-vivo biomarkers
Industry: Medical Imaging

Drug pipeline

1 asset

fluoroestradiol F-18

Commercial

Indications: Metastatic breast cancer, Recurrent breast cancer

Beyond the preview

Go deeper on Zionexa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zionexa.

Explore the full profile